Author: Matthew Ettinger
-
Why the Psychedelic-Assisted Care Field Needs an Association — And Why We Hope It’s Us
If you’re reading this, you already know something the rest of the world is just catching up on: this work is powerful, it’s hard, and it’s lonely in ways that surprise even the most prepared practitioner. You went through training, built a practice or joined a service center, and somewhere along the way realized no…
-
FDA – Public Comments
Dear NPA Community, This is a pivotal moment. The FDA has announced a public hearing on the future of psychedelic therapy, and they are actively seeking input from patients, practitioners, advocates, and the broader community. On September 14, 2026, the FDA will hold its Considerations for Potential Future Therapeutic Use of Psychedelic Drugs Public Hearing.…
-
100+ Joined Our Virtual Community Session Recently, Where we Shared Critical Infrastructure Advancements
On December 16th, the National Psychedelics Association (the NPA) convened a well-attended virtual briefing over Zoom, bringing together facilitators, service center operators, training providers, and allied professionals from across Oregon, Colorado, and even beyond. The session was structured as a working update rather than a formal presentation, walking the community through six big benefits we offer, including…
-
Urgent Action on Psilocybin Petition
RE: Psilocybin Rescheduling Petition, Dr. Sunil Aggarwal, AIMS Institute Dear Assistant Administrator Prevoznik: This is in further follow up to your letter to Dr. Sunil Aggarwal of the AIMS Institute, dated February 3, 2025, addressing our February 2, 2022 petition to transfer psilocybin from schedule I to schedule II of the Controlled Substances Act. Pursuant…
-
Psilocybin Rescheduling
In the ongoing battle to enable access to psilocybin assisted therapy, a significant effort is focused on moving it off Schedule I of the Controlled Substances Act, which severely restricts its use to research purposes only. In February 2022, we collaborated with Dr. Aggarwal to petition the Drug Enforcement Administration (DEA) to reschedule psilocybin to…